← Back to headlines
Valneva Outlines 2026 Revenue Guidance, Pfizer Targets Lyme Decisions
Valneva has outlined its 2026 revenue guidance between $145 million and $160 million, while Pfizer aims to make decisions regarding its Lyme disease initiatives within the next 12 months.
14 Aug, 02:30 — 14 Aug, 02:30
Sources
Showing 1 of 1 sources
